GUJARAT THEMIS BIOSYN
|
GUJARAT THEMIS BIOSYN Last 5 Year Financial Ratios History
[Standalone]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 39.90 | 30.03 | 20.77 | 16.30 | 4.41 |
| CEPS(Rs) | 41.67 | 31.56 | 21.96 | 17.23 | 5.25 |
| DPS(Rs) | 5.40 | 11.00 | - | 1.65 | - |
| Book NAV/Share(Rs) | 102.66 | 71.11 | 48.14 | 29.04 | 12.75 |
| Tax Rate(%) | 25.17 | 26.10 | 26.18 | 24.26 | 21.80 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 49.82 | 50.54 | 44.53 | 37.40 | 17.93 |
| EBIT Margin(%) | 52.13 | 52.12 | 46.23 | 37.80 | 20.35 |
| Pre Tax Margin(%) | 52.00 | 51.40 | 45.14 | 36.72 | 19.96 |
| PAT Margin (%) | 38.91 | 37.98 | 33.32 | 27.81 | 15.61 |
| Cash Profit Margin (%) | 40.64 | 39.93 | 35.24 | 29.41 | 18.59 |
| Performance Ratios | |||||
| ROA(%) | 35.81 | 37.08 | 35.65 | 45.62 | 24.07 |
| ROE(%) | 45.92 | 50.35 | 53.82 | 77.99 | 41.85 |
| ROCE(%) | 61.53 | 67.91 | 67.89 | 85.96 | 44.88 |
| Asset Turnover(x) | 0.92 | 0.98 | 1.07 | 1.64 | 1.54 |
| Sales/Fixed Asset(x) | 4.12 | 4.27 | 3.82 | 4.25 | 2.65 |
| Working Capital/Sales(x) | 3.27 | 1.88 | 1.91 | 7.22 | -8.60 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.24 | 0.23 | 0.26 | 0.24 | 0.38 |
| Receivable days | 52.71 | 63.29 | 70.42 | 55.80 | 37.88 |
| Inventory Days | 32.13 | 28.06 | 24.34 | 13.65 | 3.55 |
| Payable days | 114.42 | 115.10 | 132.50 | 215.31 | 1,966.91 |
| Valuation Parameters | |||||
| PER(x) | 17.20 | 13.57 | 9.80 | 5.96 | 8.91 |
| PCE(x) | 16.47 | 12.91 | 9.27 | 5.64 | 7.48 |
| Price/Book(x) | 6.69 | 5.73 | 4.23 | 3.35 | 3.08 |
| Yield(%) | 0.79 | 2.70 | - | 1.70 | - |
| EV/Net Sales(x) | 6.63 | 5.05 | 3.00 | 1.73 | 1.50 |
| EV/Core EBITDA(x) | 12.31 | 9.33 | 6.22 | 4.39 | 6.41 |
| EV/EBIT(x) | 12.72 | 9.68 | 6.48 | 4.58 | 7.35 |
| EV/CE(x) | 5.29 | 4.23 | 2.76 | 2.07 | 1.87 |
| M Cap / Sales | 6.69 | 5.15 | 3.27 | 1.66 | 1.39 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 29.71 | 26.82 | 6.39 | 107.37 | 5.80 |
| Core EBITDA Growth(%) | 29.22 | 42.43 | 29.97 | 250.30 | 49.51 |
| EBIT Growth(%) | 29.74 | 42.99 | 30.09 | 285.20 | 58.95 |
| PAT Growth(%) | 32.88 | 44.55 | 27.48 | 269.40 | 65.73 |
| EPS Growth(%) | 32.88 | 44.55 | 27.47 | 269.40 | 65.73 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | 0.04 | 0.19 | 0.32 |
| Current Ratio(x) | 2.28 | 2.93 | 2.84 | 1.49 | 0.63 |
| Quick Ratio(x) | 1.87 | 2.57 | 2.60 | 1.24 | 0.60 |
| Interest Cover(x) | 386.97 | 72.31 | 42.66 | 34.85 | 52.71 |
| Total Debt/Mcap(x) | - | - | 0.01 | 0.06 | 0.11 |
Compare Financial Ratios of peers of GUJARAT THEMIS BIOSYN
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GUJARAT THEMIS BIOSYN | ₹2,902.5 Cr | -0.2% | 3.4% | 184.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹356,001.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
| CIPLA | ₹108,813.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹100,075.0 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,325.3 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹96,553.2 Cr | 5% | 10.4% | 109.1% | Stock Analytics | |
GUJARAT THEMIS BIOSYN Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GUJARAT THEMIS BIOSYN | -0.2% |
3.4% |
184.7% |
| SENSEX | 0.5% |
1.4% |
23.5% |
You may also like the below Video Courses
